NovoCure Ltd (NVCR) is a global oncology company that pioneers the development of a ground-breaking life-extending technology for patients with solid tumors. The company is known for specializing in tumor-treating fields, an anti-mitotic treatment method that uses low-intensity electric fields to disrupt cancer cell division, thus stalling tumor growth and causing affected cancer cells to die. This unique treatment method is not based on the chemical compound basis that most traditional cancer treatments are based on, which sets NovoCure apart in the medical field.
The flagship product of NovoCure, Optune®, has the potential to significantly improve survival rates for glioblastoma patients. It is a portable, non-invasive device that targets tumor cells with its electric field technology. This innovative product was awarded Humanitarian Use Device designation by the FDA in the United States and has also secured regulatory approvals in the European Union, Japan, and other regions.
NovoCure’s innovative technology and approach are rooted in more than a decade of scientific research into the use of electric fields for therapeutic purposes, and it continues to be at the forefront of research in this arena. Multiple clinical trials are underway to evaluate the efficacy of tumor-treating field technology in different cancer types, including pancreatic, ovarian, and lung cancers.
NovoCure, based in Jersey, British Isles, has a significant global presence with operations in the U.S., Europe, and Asia. As of December 2021, the company had treated more than 18,000 patients worldwide with its unique technology, making a significant difference in the field of cancer care.
The company is publicly traded on the NASDAQ Global Select Market under the ticker symbol NVCR. Despite being a relatively young company, founded in 2000, NovoCure has established itself as a leading innovator in the oncology market, earning recognition and trust from the medical community and patients alike.
To sum up, NovoCure Ltd is more than just a typical oncology company - it is a pioneering innovator dedicated to improving and prolonging the lives of cancer patients around the world. Its unique approach and trailblazing technology represent a revolutionary step forward in the quest to conquer one of humanity's deadliest diseases.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
NovoCure (NVCR) is back in focus following a board change and new validation for its TTFields therapy in various cancer indications. Despite a recent 23.86% year-to-date gain, the stock has seen an 86.01% decline over five years, raising questions about whether current gains are due to clinical validation or a market correction. The company is considered 38% undervalued by some, with a fair value of $26.07, banking on the wider adoption and reimbursement of its TTFields therapy.
NovoCure's stock has fallen 86% over the past five years, prompting questions about its current valuation relative to sales. Despite a P/S ratio similar to the Medical Equipment industry average, a tailored benchmark suggests NovoCure might be undervalued when considering its growth, margins, size, and risk. Investors are encouraged to consider these fundamentals and specific concerns raised by a broader review before making investment decisions.
NovoCure (NVCR) is considered 36% undervalued, trading at $16.67 against a fair value estimate of $26.07, despite a recent board change and some share price volatility. The company's future potential is linked to the validation of its TTFields therapy for new indications and projected market expansion. However, slower than hoped adoption and persistent losses pose risks to this valuation.
_07_03_2026_03_50_21_133108.jpg)
NovoCure (NASDAQ: NVCR) has announced a board vacancy following the departure of Timothy Scannell, effective September 2, 2026. The company stated that Scannell's retirement was in accordance with the company's Articles of Association and was not due to any disagreements with management or the organization. Chief Financial Officer Christoph Brackmann authorized the report confirming the director seat was formally vacated.
Novocure Limited disclosed a cybersecurity incident in mid-August 2026, resulting in the exposure of internal patient IDs for over 1,400 U.S. patient records, additional identifying information for fewer than 50 other patients, and general contact information for healthcare providers and employees. The company stated that its medical treatment devices were not accessed and systems remained functional. This incident is part of a trend of cybersecurity breaches affecting the healthcare and medtech industries in 2026.
Novocure Limited recently disclosed a cybersecurity incident in mid-August 2026, which exposed internal patient ID numbers for over 1,400 U.S. patient records, along with additional identifying information for fewer than 50 other patients. The breach also affected general contact information for healthcare providers and Novocure employees. Despite this, the company stated its medical treatment devices were not accessed, systems remained functional, and it does not anticipate a material financial impact, highlighting growing cybersecurity concerns in the healthcare industry.
Oncology company Novocure reported a cyberattack in mid-August that exposed internal records of over 1,400 U.S. patients, including company patient IDs and contact information for healthcare providers and employees. While access to medical treatment devices was not gained and all systems are functional, the incident adds to a growing number of cyberattacks in the healthcare sector. Novocure anticipates no material financial impact from the breach.
NovoCure (NVCR) has seen an 18.1% gain over the past four weeks, with Wall Street analysts projecting a potential 50.9% upside based on a mean price target of $27.14. Despite a high standard deviation in individual targets, analyst optimism about the company's earnings prospects, supported by upward EPS estimate revisions and a Zacks Rank #2 (Buy), suggests a legitimate reason for potential stock upside. However, the article cautions against solely relying on price targets due to their inherent biases and historical unreliability.